published meta-analysis   sensitivity analysis   studies

ivermectin in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsSeet 2021, 2021 1.00 [0.02; 50.64] 1.00[0.02; 50.64]Seet 2021, 202110%1,236NAnot evaluable new illness compatible with Covid-19 detailed resultsSeet 2021, 2021 0.03 [0.02; 0.04] 0.03[0.02; 0.04]Seet 2021, 202110%1,236NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-05-21 09:26 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 684,886 - roots T: 290